1. Home
  2. CUE vs IZEA Comparison

CUE vs IZEA Comparison

Compare CUE & IZEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • IZEA
  • Stock Information
  • Founded
  • CUE 2014
  • IZEA 2006
  • Country
  • CUE United States
  • IZEA United States
  • Employees
  • CUE N/A
  • IZEA N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • IZEA Advertising
  • Sector
  • CUE Health Care
  • IZEA Consumer Discretionary
  • Exchange
  • CUE Nasdaq
  • IZEA Nasdaq
  • Market Cap
  • CUE 59.5M
  • IZEA 60.8M
  • IPO Year
  • CUE 2018
  • IZEA N/A
  • Fundamental
  • Price
  • CUE $0.83
  • IZEA $4.22
  • Analyst Decision
  • CUE Strong Buy
  • IZEA
  • Analyst Count
  • CUE 2
  • IZEA 0
  • Target Price
  • CUE $3.00
  • IZEA N/A
  • AVG Volume (30 Days)
  • CUE 118.2K
  • IZEA 93.4K
  • Earning Date
  • CUE 08-12-2025
  • IZEA 08-12-2025
  • Dividend Yield
  • CUE N/A
  • IZEA N/A
  • EPS Growth
  • CUE N/A
  • IZEA N/A
  • EPS
  • CUE N/A
  • IZEA N/A
  • Revenue
  • CUE $8,286,000.00
  • IZEA $36,935,906.00
  • Revenue This Year
  • CUE N/A
  • IZEA $16.46
  • Revenue Next Year
  • CUE $23.84
  • IZEA $15.95
  • P/E Ratio
  • CUE N/A
  • IZEA N/A
  • Revenue Growth
  • CUE N/A
  • IZEA 12.49
  • 52 Week Low
  • CUE $0.45
  • IZEA $1.68
  • 52 Week High
  • CUE $1.99
  • IZEA $4.39
  • Technical
  • Relative Strength Index (RSI)
  • CUE 53.58
  • IZEA 62.20
  • Support Level
  • CUE $0.77
  • IZEA $4.04
  • Resistance Level
  • CUE $0.84
  • IZEA $4.38
  • Average True Range (ATR)
  • CUE 0.06
  • IZEA 0.29
  • MACD
  • CUE -0.00
  • IZEA 0.01
  • Stochastic Oscillator
  • CUE 71.90
  • IZEA 80.90

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

Share on Social Networks: